Clinical Trial Update: Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study evaluating safety, maximum tolerated dose and pharmacokinetics of a single subcutaneous dose of TransCon PEG Treprostinil in hea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• TransCon PEG Treprostinil (treprostinil (PEGylated prodrug))

Snippet

Sponsor: United Therapeutics | Conditions: PAH | Phase 1 | Status: WITHDRAWN